321 related articles for article (PubMed ID: 28655469)
1. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
2. 9-Phenanthrol enhances the generation of an CD8
Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
[TBL] [Abstract][Full Text] [Related]
3. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
[TBL] [Abstract][Full Text] [Related]
5. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
6. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
Stein P; Weber M; Prüfer S; Schmid B; Schmitt E; Probst HC; Waisman A; Langguth P; Schild H; Radsak MP
PLoS One; 2011; 6(11):e27911. PubMed ID: 22114725
[TBL] [Abstract][Full Text] [Related]
8. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
10. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
11. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.
Klavinskis LS; Whitton JL; Oldstone MB
J Virol; 1989 Oct; 63(10):4311-6. PubMed ID: 2476571
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells efficiently induce protective antiviral immunity.
Ludewig B; Ehl S; Karrer U; Odermatt B; Hengartner H; Zinkernagel RM
J Virol; 1998 May; 72(5):3812-8. PubMed ID: 9557664
[TBL] [Abstract][Full Text] [Related]
13. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
[TBL] [Abstract][Full Text] [Related]
14. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
[TBL] [Abstract][Full Text] [Related]
15. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice.
van der Most RG; Murali-Krishna K; Whitton JL; Oseroff C; Alexander J; Southwood S; Sidney J; Chesnut RW; Sette A; Ahmed R
Virology; 1998 Jan; 240(1):158-67. PubMed ID: 9448700
[TBL] [Abstract][Full Text] [Related]
16. Impact of CCR7 on priming and distribution of antiviral effector and memory CTL.
Junt T; Scandella E; Förster R; Krebs P; Krautwald S; Lipp M; Hengartner H; Ludewig B
J Immunol; 2004 Dec; 173(11):6684-93. PubMed ID: 15557160
[TBL] [Abstract][Full Text] [Related]
17. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus.
Moskophidis D; Zinkernagel RM
J Virol; 1995 Apr; 69(4):2187-93. PubMed ID: 7533851
[TBL] [Abstract][Full Text] [Related]
18. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
Dell K; Koesters R; Gissmann L
Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
[TBL] [Abstract][Full Text] [Related]
19. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.
Sedlik C; Dadaglio G; Saron MF; Deriaud E; Rojas M; Casal SI; Leclerc C
J Virol; 2000 Jul; 74(13):5769-75. PubMed ID: 10846055
[TBL] [Abstract][Full Text] [Related]
20. Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice.
Holst PJ; Christensen JP; Thomsen AR
J Immunol; 2011 Apr; 186(7):3997-4007. PubMed ID: 21357263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
